Historical record - last NADAC publication: 6/17/2020
PANCREAZE DR 4,200 UNIT CAP
PANCRELIPASE LIPASE, PANCRELIPASE AMYLASE, and PANCRELIPASE PROTEASEStrength
24600; 4200; 14200 [USP'U]/1; [USP'U]/1; [USP'U]/1
Manufacturer
Vivus LLCNDC
62541040210
Classification
Brand
Dosage Form
CAPSULE, DELAYED RELEASE
Route
ORAL
Last Updated
6/17/2020
Active Ingredients
PANCRELIPASE AMYLASE; PANCRELIPASE LIPASE; PANCRELIPASE PROTEASEApproval Type
Biologic (BLA)
FDA Application
BLA022523On Market Since
4/12/2010
Price Statistics
The NADAC for PANCREAZE DR 4,200 UNIT CAP has been published 53 times since Jun 17, 2020, and over the history we have for it it has held within roughly two percent of its current level. The table below summarizes its recorded NADAC range and movement.
| Current price | $1.1440 per EA |
|---|---|
| All-time high | $1.1440 (Jun 16, 2021) |
| All-time low | $1.1440 (Jun 17, 2020) |
| Median price | $1.1440 |
| Average price | $1.1440 |
| Largest weekly change | 0.0% (Jun 24, 2020) |
| Weeks tracked | 53 |
| Tracking since | Jun 17, 2020 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient, strength, and dosage form. Compare the broader picture on the PANCRELIPASE LIPASE, PANCRELIPASE AMYLASE, and PANCRELIPASE PROTEASE market page.
Lowest-Cost Alternatives
No alternatives available
Frequently asked questions
What is the NADAC price of PANCREAZE DR 4,200 UNIT CAP?
The current National Average Drug Acquisition Cost (NADAC) for PANCREAZE DR 4,200 UNIT CAP, manufactured by Vivus LLC, is $1.1440 per EA (NDC 62541040210), effective Jun 16, 2021.
How has the price of PANCREAZE DR 4,200 UNIT CAP changed over time?
Over the history we have for it, the NADAC for PANCREAZE DR 4,200 UNIT CAP has held within roughly two percent of its current level. It has been tracked across 53 weekly CMS publications since Jun 17, 2020.
What are the highest and lowest recorded NADAC prices for PANCREAZE DR 4,200 UNIT CAP?
Since Jun 17, 2020, the NADAC for PANCREAZE DR 4,200 UNIT CAP has ranged from a low of $1.1440 (Jun 17, 2020) to a high of $1.1440 (Jun 16, 2021), with a median of $1.1440 per EA.
Are there cheaper alternatives to PANCREAZE DR 4,200 UNIT CAP?
No other NADAC-published product currently shares the active ingredient, strength, and dosage form of PANCREAZE DR 4,200 UNIT CAP, so no direct lower-cost alternative is listed.
Who manufactures PANCREAZE DR 4,200 UNIT CAP?
PANCREAZE DR 4,200 UNIT CAP (NDC 62541040210) is labeled by Vivus LLC, and CMS classifies it as a brand product.
Related Drugs
Same classification